Business Context and Reporting Period
This Form 8-K Current Report was filed by Global Medical REIT Inc. (not Chiron Real Estate Inc.) on August 17, 2020. The filing reports the entry into a Material Definitive Agreement regarding a new equity distribution facility.
Key Financial Metrics and Transaction Details
- Transaction Type: Entry into a Sales Agreement for an "at-the-market" (ATM) offering and forward sale program.
- Aggregate Offering Size: Up to $150,000,000 in gross proceeds.
- Securities Involved: Common Stock, par value $0.001 per share (Trading Symbol: GMRE).
- Compensation: Agents and Forward Sellers are entitled to compensation of up to 2.0% of gross proceeds or a reduction in the initial forward price.
- Financial Impact: The filing does not provide current revenue, profit, cash flow, or debt figures. Proceeds will only be received upon the actual sale of shares or settlement of forward contracts.
Material Changes and Transaction Mechanics
The Company entered into a Sales Agreement with multiple sales agents (including BMO Capital Markets, J.P. Morgan, and Wells Fargo) and forward purchasers. Key mechanics include:
- At-the-Market Sales: The Company may sell shares through agents in ordinary brokerage transactions on the NYSE.
- Forward Sales: Forward Purchasers may borrow and sell shares on the Company's behalf. The Company does not receive proceeds initially but expects to settle these agreements physically (delivering shares for cash) or via cash/net-share settlement.
- Flexibility: The Company has no obligation to sell any shares and may suspend the program at any time.
Guidance, Risks, and Contingencies
- Settlement Risk: If the Company elects to cash settle a Forward Sale Agreement, it may not receive proceeds and could owe cash to the Forward Purchaser. If net-share settled, the Company may owe shares without receiving cash.
- Market Conditions: Sales are subject to market conditions and the commercially reasonable efforts of the agents.
- Legal Status: The offering is subject to the Company's Registration Statement on Form S-3 and applicable state securities laws.
Investor Verification Checklist
- Verify the actual volume of shares sold and proceeds received under this agreement in subsequent quarterly reports (10-Q) or annual reports (10-K).
- Monitor the Company's share count for dilution resulting from the issuance of shares under this $150 million facility.
- Review the full text of the Sales Agreement (Exhibit 1.1) and Master Forward Confirmation (Exhibit 99.1) for specific termination rights and settlement terms.
- Confirm whether the Company has elected to use the forward sale component, as this creates potential future obligations without immediate cash inflow.